Saamir Hassan
Cardiovascular Disease · Houston, TXNPI 1932352572
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,020 of the $7,445 with a category attached, or 94.3%. Tersera Therapeutics LLC accounts for 94.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $7,020 and has fallen 99.2% since, to $58 in 2025.
Across 7 payments — averaging $1063.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tersera Therapeutics LLC$7K
- Surmodics, Inc.$191
- Impulse Dynamics (USA) Inc.$149
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$26
- Boston Scientific$20
- E.r. Squibb & Sons, L.L.C.$20
- plus $18 from 1 others
Across 15 payments — averaging $32,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tersera Therapeutics LLC$488K
What the payments were for
- Consulting fees$7,02094%
- Food & beverage$4256%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tersera Therapeutics LLC | 1 | $7,020 |
| Surmodics, Inc. | 1 | $191 |
| Impulse Dynamics (USA) Inc. | 1 | $149 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Boston Scientific | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,445 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $179,462 |
| EntrestoSacubitril/Valsartan | 31 | $49,351 |
| XareltoRivaroxaban | 38 | $39,111 |
| BrilintaTicagrelor | 15 | $16,331 |
| Repatha SureclickEvolocumab | 11 | $11,238 |
| Metoprolol Succinate | 206 | $2,505 |
| Nifedipine ErNifedipine | 78 | $1,754 |
| Carvedilol | 185 | $1,335 |
| Torsemide | 41 | $1,261 |
| Atorvastatin Calcium | 138 | $1,190 |
| Prasugrel Hcl | 17 | $1,155 |
| Losartan Potassium | 97 | $954 |
| Metoprolol Tartrate | 128 | $833 |
| Amlodipine Besylate | 141 | $802 |
| Rosuvastatin Calcium | 69 | $788 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Houston
- Biykem BozkurtHouston$606K
- Reynolds DelgadoHouston$471K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.